感谢40楼swipernosweiping Q: Recently there was some reporting that China's Wuhan Virology Institute together with the Chinese Military , they applied for the patent of Remdesivir. So obviously this is a delicate balance between fighting the epidemic, saving lives, IP protection question. So it's a little bit probably delicate. But I do want to know what is Gilead's reaction to the application and what's Gilead's stance if China's IP authority approves this application, and how we're going to continue to manage the control of Remdesivir development and also retaining the right to help fighting the epidemic.
A: Thank you so much. It's a very relevant question. And obviously it just came out overnight, and like everything with regard to Remdesivir, ah, you know we are moving as quickly as we can. I think my message to you and everybody is that has no impact on what we are going to do with global health. I just want to be tremendously clear here that our responsibility is the patients. And our responsibility is number one: pursue the right clinical programs to determine whether or not this medicine has impact with patients or not, and it'll be driven by the science, by the clinical evidence. And at the same time, ramping our production up, in the event that it does, we can get this medicine to as many patients around the globe as needed. Patent is not at the forefront of our minds. I will say, ‘cause I checked with our patent colleagues, that as we would with any medicine at Gilead, we have patents on Remdesivir, not only for the compound, but also for all of its use including coronavirus in regions around the world. But we will not get into a patent dispute, we will find a way to help patients, and of course, we will protect our intellectual property as a separate step of the process. But patients first. (谢谢86楼sillynut的翻译，我想告诉所有人这件事对我们发展全球医疗事业没有影响。我想要非常清楚的告诉大家我们的责任在于患者。排在首要位置的是找到正确的临床操作，看这种药是否对患者有效。这一过程必须经过科学证明和临床检验。同时我们要加速提高产量，以便有需要时我们的药可以送到世界上任何一个患者手上。专利还不是我们目前关注的问题。我已经跟公司负责专利的同事沟通过，我们拥有对这个药的专利，不仅是成份结构专利，还有在世界上任何地区的应用专利，包括非冠病毒。我们不希望现在卷入专利纷争，我们需要找到帮助病人的方法。我们会在其他渠道寻求自己的知识产权保护。但现在患者第一。)
Q: Recently there was some reporting that China's Wuhan Virology Institute together with the Chinese Military Academy, they applied for the patent of Remdesivir. So obviously this is a delicate balance between fighting the epidemic, saving lives, vs IP protection question. So it's a little bit probably delicate. But I do want to know what is Gilead's reaction to the application and what's Gilead's stance if China's IP authority approves this application, and how we're going to continue to manage the control of Remdesivir development and also retaining the right to help fighting the epidemic.
A: Thank you so much. It's a very relevant question. And obviously it just came out overnight, and like everything with regard to Remdesivir, ah, you know we are moving as quickly as we can. I think my message to you and everybody is that has no impact on what we are going to do with global health. I just want to be tremendously clear here that our responsibility is the patients. And our responsibility is number one: pursue the right clinical programs to determine whether or not this medicine has impact with patients or not, and it'll be driven by the science, by the clinical evidence. And at the same time, ramping our production up, in the event that it does, we can get this medicine to as many patients around the globe as needed. Patent is not at the forefront of our minds. I will say, ‘cause I checked with our patent colleagues, that as we would with any medicine at Gilead, we have patents on Remdesivir, not only for the compound, but also for all of its use including coronavirus in regions around the world. But we will not get into a patent dispute, we will find a way to help patients, and of course, we will protect our intellectual property as a separate step of the process. But patients first.
系统提示：若遇到视频无法播放请点击下方链接
https://twitter.com/i/videos/1225142688447467520
系统提示：若遇到视频无法播放请点击下方链接
https://video.twimg.com/ext_tw_video/1225142527948275712/pu/vid/368x640/fI775Y0lAn2M93fX.mp4?tag=10
Gilead 公司会议：有人问CEO有关武汉病毒所的专利申请，CEO 的回答要点：我们只关注药是否有效，以及有效的药物能够及时到患者手上。我们关心的是患者，患者第一！（patients first!)
感谢40楼swipernosweiping Q: Recently there was some reporting that China's Wuhan Virology Institute together with the Chinese Military , they applied for the patent of Remdesivir. So obviously this is a delicate balance between fighting the epidemic, saving lives, IP protection question. So it's a little bit probably delicate. But I do want to know what is Gilead's reaction to the application and what's Gilead's stance if China's IP authority approves this application, and how we're going to continue to manage the control of Remdesivir development and also retaining the right to help fighting the epidemic.
A: Thank you so much. It's a very relevant question. And obviously it just came out overnight, and like everything with regard to Remdesivir, ah, you know we are moving as quickly as we can. I think my message to you and everybody is that has no impact on what we are going to do with global health. I just want to be tremendously clear here that our responsibility is the patients. And our responsibility is number one: pursue the right clinical programs to determine whether or not this medicine has impact with patients or not, and it'll be driven by the science, by the clinical evidence. And at the same time, ramping our production up, in the event that it does, we can get this medicine to as many patients around the globe as needed. Patent is not at the forefront of our minds. I will say, ‘cause I checked with our patent colleagues, that as we would with any medicine at Gilead, we have patents on Remdesivir, not only for the compound, but also for all of its use including coronavirus in regions around the world. But we will not get into a patent dispute, we will find a way to help patients, and of course, we will protect our intellectual property as a separate step of the process. But patients first.
(谢谢86楼sillynut的翻译，我想告诉所有人这件事对我们发展全球医疗事业没有影响。我想要非常清楚的告诉大家我们的责任在于患者。排在首要位置的是找到正确的临床操作，看这种药是否对患者有效。这一过程必须经过科学证明和临床检验。同时我们要加速提高产量，以便有需要时我们的药可以送到世界上任何一个患者手上。专利还不是我们目前关注的问题。我已经跟公司负责专利的同事沟通过，我们拥有对这个药的专利，不仅是成份结构专利，还有在世界上任何地区的应用专利，包括非冠病毒。我们不希望现在卷入专利纷争，我们需要找到帮助病人的方法。我们会在其他渠道寻求自己的知识产权保护。但现在患者第一。)
参照武汉病毒所的操作和表态，个人觉得是大型辱华现场，内心百味杂陈。
PS：看到有人说虚伪，即使他真的是虚伪的，私底下跟朋友骂了很多CNM，但是他作为CEO代表公司的公开表态是非常正面的，是符合普世价值的。相比之下，我惭愧的是"武毒所"代表的，在中国通行的价值观见不得人，要知道武毒所可是打着爱国的大旗冠冕堂皇抢注专利的，官媒是正面报道的，这才是让我作为华人觉得无地自容的地方。
评论提到股票，我觉得这可能真的是家慈悲为主，赚钱为辅的公司，因为他们开发人民的希望本来是为了埃博拉病毒，目标客户在非洲，这显然就不是冲着赚钱去的，所以我真心相信CEO所说的就是公司上下的想法。遗憾的是很多中国人即使用人民的希望治好之后，也很可能只知道感谢祖国感谢党，而从来不知道曾经有这么一家叫Gilead的美国公司投入巨资研发，为中国人民的福祉付出过。
"你看看人家”，上一次这种感觉，是知道日本官员自杀。
谢谢确认。
人必先自辱而后人辱之。。。
我很高兴自己是part of“人家”。
手动点赞，就当间接做慈善。
感谢文字版，人也说了已经有专利啊，病毒所的人这是疯了吗
月初卖啊？那内部消息是反指呀。。。
你可以去查一下，我是前几天在一个中文论坛上看到有人提到，当时随手查的是1月初卖了，细节我没跟进，也许人家是正常行使权利，赶巧罢了。所以我才说华人反射弧好长，今天才提到他家股票
CEO自己都说接下来几年非常challenging , 现在基本就靠HIV挣钱，要想维持之前几年的growth很难。我不懂财务，但是想到美剧Sillicon valley有一个桥段说，start up想圈钱一定不能盈利，一开始盈利投资人就有expectation了，越烧钱人反而家越觉得你有potential. 感觉花街也是这种脑回路
就算虚伪、人家起码表面做善事，那你这个不虚伪的就是把恶写在脸上，对吧？ 鲁迅说过：我向来是不惮以最坏的恶意揣测中国人。这么多年了，鲁迅要是没死估计还会这样说
丙肝药可以治愈病人，病人量越来越小，利润降低速度很快。不只他家，前几年做丙肝的几大药厂都面临同样的问题，有的减产有的已经停产。药厂股票好不好还是要看现有的药卖的好不好和后续的pipelines够不够强大，G家这方面的确不是很强。在研发的药滑铁卢的太多，人民的希望目前也没有确定有效，即使有效结局基本上跟丙肝药差不多，而且全球病患数量更小，股价没有太多反应是正常的。
武毒所在这次疫情爆发后一直安静如死鸡，然后就突然冒出来干了一件low穿地心的事
哪里一直安静，双黄连也是人家中国居里夫人的杰作呀
是的，Gilead家的丙肝药是彻底治愈，不需要一直吃药，我爸爸就是吃他家的药治好的，一个疗程痊愈，不复发。Gilead真的是良心企业，大赞~
很多人加仓，长期说不定会好，希望善有善报吧
微信就可以啊
真有水平
再比比中国外交部，拿屁股当脸。
真是丢人啊。还有脸出来洗地。
估计做的太多了，不觉得有问题了。
搞得我想支持它家了。
还有双黄连。。。不止一件了。唉。
每一个满口国家利益的人，其实心里满满都是自己的利益。流氓不可怕，就怕流氓有文化！遗憾的是墙内好些人真的信这个，哎~
武汉肺炎不仅对肺影响很大，还看出一些人脑子有问题。
反正美国人怎么做都是错，给你帮助说人虚伪，不给帮助不知道要被你喷成怎样了，所以你自己想想自己是不是已经被仇恨教育洗坏了脑子。
FDA批不批有什么意义，美国政府及时撤侨，停航，人家美国根本不需要这个药。中国那边草包行政导致疫情危害全球，每天一幕幕人间惨剧就指着它救命，连双黄连都抢光了，这个药你还怕没人买吗？双赢个屁，筹码个腿，如果试验有效，应该在天安门给Gilead立碑感谢人家危难之中救民于水火。我都不知道你什么逻辑，你这相当于快溺死的人还伸个巴掌出来跟救援队讨价还价，说你救我其实是双赢。
是打算把20美元一份的药还价到10美元吗，这药卖的比双黄连还便宜吧